1. Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis
   Bogdan Silviu Ungureanu et al, 2021, Frontiers in Oncology CrossRef
2. Predictive biomarkers in gastric cancer
   C. Röcken, 2023, Journal of Cancer Research and Clinical Oncology CrossRef
3. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy
   Zhe Ma et al, 2024, Cancer Immunology, Immunotherapy CrossRef
4. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
   Amin Daei Sorkhabi et al, 2023, Frontiers in Immunology CrossRef
5. Combined score of Y chromosome loss and T-cell infiltration improves UICC based stratification of esophageal adenocarcinoma
   Verena Maria Raters et al, 2023, Frontiers in Oncology CrossRef
6. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
   Kohei Shitara et al, 2024, Gastric Cancer CrossRef
7. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
   Erkan Kayikcioglu et al, 2023, World Journal of Gastrointestinal Oncology CrossRef
8. The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer
   Yongji Zeng et al, 2024, Expert Opinion on Drug Discovery CrossRef
9. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers
   Weixiang Zhong et al, 2022, Frontiers in Immunology CrossRef
10. High Expression of CLDN 18.2 is Associated with Poor Disease-Free Survival of HER-2 Positive Gastric Cancer
    Tongxin Zhang et al, 2024, International Journal of General Medicine CrossRef